Evidence map›Paper›PMID 35008699›Full record

ArticleInternational journal of molecular sciences2021

MicroRNA-30b Is Both Necessary and Sufficient for Interleukin-21 Receptor-Mediated Angiogenesis in Experimental Peripheral Arterial Disease.

Tao Wang, Liang Yang, Mingjie Yuan, Charles R Farber, Rosanne Spolski, Warren J Leonard, Vijay C Ganta, Brian H Annex

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Cytokines and microRNAs in SARS-CoV-2: What do we know?Molecular therapy. Nucleic acids · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Tao WangState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, Guangzhou Medical University, Guangzhou 510120, China.ORCID 0000-0001-9372-1648
Liang YangRobert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-8242-6977
Mingjie YuanRobert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA 22908, USA.
Charles R FarberCenter for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA.
Rosanne SpolskiLaboratory of Molecular Immunology and the Immunology Center, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Warren J LeonardLaboratory of Molecular Immunology and the Immunology Center, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Vijay C GantaRobert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-2967-8320
Brian H AnnexRobert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-6538-8243
Augusta University Health · USNational Institutes of Health · USNankai University · CNState Key Laboratory of Respiratory Disease · CNUniversity of Virginia · USWuhan University · CN

Funding

Clinical Phenotyping and Disease Specific Sampling to Identify Non-coding RNAs for Human Therapeutics in PADR01HL150003 · NHLBI · AUGUSTA UNIVERSITY · PI ANNEX, BRIAN H, MCCLUNG, JOSEPH MATTHEW · 2020 to 2023
$3.0M
Precision Medicine for Therapeutic Angiogenesis in Peripheral Arterial Disease: Targeting of the IL21R PathwayR01HL148590 · NHLBI · AUGUSTA UNIVERSITY · PI ANNEX, BRIAN H · 2019 to 2022
$2.9M
The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery DiseaseR01HL141325 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H · 2019 to 2022
$2.7M
A Two Amino Acid Switch in the Anti-angiogenic VEGF165b isoform creates a Novel Agent for Therapeutic Angiogenesis in Peripheral Artery DiseaseR01HL146673 · NHLBI · UNIVERSITY OF VIRGINIA · PI GANTA, VIJAY CHAITANYA · 2019 to 2023
$1.9M
National Institute of Health 7R01HL146673-02National Institute of Health R01GM129074National Institute of Health R01HL101200National Institute of Health R01HL148590Natural Science Foundation of China 81700426Natural Science Foundation of China 81970046NHLBI NIH HHS R01 HL141325NHLBI NIH HHS R01 HL146673NHLBI NIH HHS R01 HL148590NHLBI NIH HHS R01 HL150003NIH HHS R01HL141325NIH HHS RO1 HL121635
6 · The paper itself

Abstract

The interleukin-21 receptor (IL-21R) can be upregulated in endothelial cells (EC) from ischemic muscles in mice following hind-limb ischemia (HLI), an experimental peripheral arterial disease (PAD) model, blocking this ligand-receptor pathway-impaired STAT3 activation, angiogenesis, and perfusion recovery. We sought to identify mRNA and microRNA transcripts that were differentially regulated following HLI, based on the ischemic muscle having intact, or reduced, IL-21/IL21R signaling. In this comparison, 200 mRNAs were differentially expressed but only six microRNA (miR)/miR clusters (and among these only miR-30b) were upregulated in EC isolated from ischemic muscle. Next, myoglobin-overexpressing transgenic (MgTG) C57BL/6 mice examined following HLI and IL-21 overexpression displayed greater angiogenesis, better perfusion recovery, and less tissue necrosis, with increased miR-30b expression. In EC cultured under hypoxia serum starvation, knock-down of miR-30b reduced, while overexpression of miR-30b increased IL-21-mediated EC survival and angiogenesis. In Il21r

Indexed as

AnimalsCell SurvivalHindlimbHumansHuman Umbilical Vein Endothelial CellsIschemiaMice, TransgenicMicroRNAsModels, BiologicalMultigene FamilyMyoglobinNeovascularization, PhysiologicPerfusionPeripheral Arterial DiseasePhosphorylationReceptors, Interleukin-21MicroRNAsMirn30d microRNA, mouseMyoglobinReceptors, Interleukin-21RNA, MessengerSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 Proteingene therapyinnate immunitypre-clinical modelsvascular disease

Identifiers

PMID35008699
PMCPMC8745227
OpenAlexW4200416140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.